8ª Edição

Study demonstrates advantage of first-line lorlatinib for ALK-mutated lung cancer patients

per: Grupo Oncoclínicas
Study demonstrates advantage of first-line lorlatinib for ALK-mutated lung cancer patients

Scientific commission

Carlos Gil
Carlos Gil
Clarissa Mathias
Clarissa Mathias
Mariana Laloni
Mariana Laloni

Contributors

Fernando Maciel
Fernando Maciel
Igor Lemos Duarte
Igor Lemos Duarte

Check out the OC Journal highlights on lung cancer at the ESMO 2020 virtual congress

Covid-19 is a subject that reverberates in the most diverse spheres. During the Annual Congress of the European Society for Medical Oncology (ESMO) it was no different. Several articles were dedicated to it, including relating it to cancer.

TERAVOLT, for example, confirmed that people diagnosed with lung cancer are also at increased risk of dying from Covid-19 if they become infected. This research is the result of an international collaboration that brought together scientists from countries such as Spain, the United States, Italy, France and Switzerland. As of 12 July, 1,012 patients from 20 countries had been recruited. All already had lung cancer when they were diagnosed with Covid-19. For Igor Lemos Duarte, an oncologist at the Centro Paraibano de Oncologia, a clinic of the Grupo Oncoclínicas in João Pessoa, this investigation is essential. “Patients with lung cancer, once diagnosed with Covid-19, may experience an exacerbation of respiratory symptoms, often attributable to the worsening of the neoplasm, but which, in fact, are due to the viral infection in its acute phase”, observes the doctor. .

Another work that drew attention at the event was the phase III study CROWN, in which the advantage of first-line lorlatinib was observed for patients with non-small cell lung cancer positive for ALK gene alterations compared to first-line crizotinib. He evaluated progression-free survival, that is, the period after treatment when the cancer remains stable. “For tumors that present specific mutations, the use of target-specific tyrosine kinase inhibitor drugs is the best treatment strategy”, says Fernando Maciel, clinical oncologist at the Triângulo Oncological Center, a clinic of the Oncoclínicas Group in Minas Gerais. For tumors that do not have genetic mutations, first-line treatment is predominantly based on chemotherapy and immunotherapy, depending on the status of PD-L1 expression as well as the contraindications to immunotherapy or chemotherapy.

Read the full report below.

Access the full article of this study
Download
Share
Or share the link
Link copied to your desktop.L